- Home
- BQ vs KLTO Comparison
BQ vs KLTO Comparison
Compare BQ & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- KLTO
- Stock Information
- Founded
- BQ 2008
- KLTO 2019
- Country
- BQ China
- KLTO United States
- Employees
- BQ N/A
- KLTO N/A
- Industry
- BQ Other Specialty Stores
- KLTO
- Sector
- BQ Consumer Discretionary
- KLTO
- Exchange
- BQ Nasdaq
- KLTO NYSE
- Market Cap
- BQ 6.0M
- KLTO 5.9M
- IPO Year
- BQ 2020
- KLTO N/A
- Fundamental
- Price
- BQ $2.00
- KLTO $0.71
- Analyst Decision
- BQ
- KLTO
- Analyst Count
- BQ 0
- KLTO 0
- Target Price
- BQ N/A
- KLTO N/A
- AVG Volume (30 Days)
- BQ 42.2K
- KLTO 84.5M
- Earning Date
- BQ 07-07-2025
- KLTO 08-15-2025
- Dividend Yield
- BQ N/A
- KLTO N/A
- EPS Growth
- BQ N/A
- KLTO N/A
- EPS
- BQ N/A
- KLTO N/A
- Revenue
- BQ $81,208,354.00
- KLTO N/A
- Revenue This Year
- BQ N/A
- KLTO N/A
- Revenue Next Year
- BQ N/A
- KLTO N/A
- P/E Ratio
- BQ N/A
- KLTO N/A
- Revenue Growth
- BQ N/A
- KLTO N/A
- 52 Week Low
- BQ $1.62
- KLTO $0.11
- 52 Week High
- BQ $7.40
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- BQ 45.05
- KLTO N/A
- Support Level
- BQ $1.92
- KLTO N/A
- Resistance Level
- BQ $2.17
- KLTO N/A
- Average True Range (ATR)
- BQ 0.17
- KLTO 0.00
- MACD
- BQ -0.01
- KLTO 0.00
- Stochastic Oscillator
- BQ 29.84
- KLTO 0.00
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.